A Research Study of How a New Medicine NNC0148-0287 C (Insulin 287) Works in the Body of People With Kidney Problems

NCT03723785 | Completed Phase 1

• 3 other identifiers: NN1436-42262017-004529-34U1111-1204-8972
• Study Type: interventional
• Target: 58
• Locations: 1 country
• Sites: 1

Brief Summary

This study will be conducted to look at the effect of decreased kidney function when getting one dose of insulin 287 and to guide dosing recommendations in people who have altered kidney function. Insulin 287 works in the body for a long time (long-acting). It is taken once a day by injecting under the skin. The main target patient group for insulin 287 is people with type 2 diabetes. Participants will get just one injection. The study will last for up to 80 days. Participants will have 11 out-patient visits with the study doctor and one in-house visit of 3 days and 2 nights. Participants will have some assessments like several blood draws, electrocardiograms (ECGs), urine collections and capillary blood sugar tests. Participants cannot take part if they are hypersensitive to the study medicine, if they received any investigational product within 90 days before screening, or if they have certain diseases e.g. HIV or hepatitis or heart problems. Participants have to take photos if they experience any allergic reactions and send them to their study doctor. Participants' kidney function will be examined by a so called "Iohexol test".

Conditions

Diabetes Mellitus, Type 2

Outcome Measures

Primary Outcomes (1)

• AUCI287,0-840h,SD: Area under the serum insulin 287 concentration-time curve after a single dose

  Measured in pmol\*h/L

  From 0 to 840 hours after trial product administration (visit 2 (study day 1))

Secondary Outcomes (6)

• Cmax,I287,SD: Maximum observed serum insulin 287 concentration after a single dose

  From 0 to tz hours after trial product administration (visit 2 (study day 1)), where tz is the time of the last quantifiable concentration

• tmax,I287,SD: Time to maximum observed serum insulin 287 concentration after a single dose

  From 0 to tz hours after trial product administration (visit 2 (study day 1)).

• Number of adverse events

  From trial product administration (visit 2 (study day 1)) until visit 13 (study day 43)

• Change in anti-insulin 287 antibody level

  From visit 2 (study day 1, pre-dose) to visit 13 (study day 43)

• Change in anti-insulin 287 antibody titres

  From visit 2 (study day 1, pre-dose) to visit 13 (study day 43)

Study Arms (5)

Participants with normal renal function

EXPERIMENTAL

Participants with normal renal function (glomerular filtration rate \[GFR\] of greater than or equal to 90 ml/min) will receive single dose of insulin 287 on Day 1.

Drug: Insulin icodec

Participants with mildly decreased renal function

EXPERIMENTAL

Participants with mildly decreased renal function (GFR of 60 to less than 90 ml/min) will receive single dose of insulin 287 on Day 1.

Drug: Insulin icodec

Participants with moderately decreased renal function

EXPERIMENTAL

Participants with moderately decreased renal function (GFR of 30 to less than 60 ml/min) will receive single dose of insulin 287 on Day 1.

Drug: Insulin icodec

Participants with severely decreased renal function

EXPERIMENTAL

Participants with severely decreased renal function (GFR of less than 30 not requiring dialysis) will receive single dose of insulin 287 on Day 1.

Drug: Insulin icodec

Participants with end-stage renal disease

EXPERIMENTAL

Participants with end-stage renal disease requiring haemodialysis will receive single dose of insulin 287 on Day 1.

Drug: Insulin icodec

Interventions

Insulin icodec DRUG

Participants will receive single dose of Insulin 287 subcutaneously (under the skin) on Day 1

Also known as: Insulin 287

Participants with end-stage renal disease; Participants with mildly decreased renal function; Participants with moderately decreased renal function; Participants with normal renal function; Participants with severely decreased renal function

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female, aged 18-75 years (both inclusive) at the time of signing informed consent.
• Body mass index between 18.5 and 32.0 kg/sqm (both inclusive).
• Meeting the pre-defined Glomerular Filtration Rate (GFR) values based on a measured GFR using an exogenous substance as tracer (renal group 1-4) or being in treatment with haemodialysis (renal group 5).

You may not qualify if:

• Known or suspected hypersensitivity to trial product or related products.
• Impaired liver function defined as Alanine Aminotransferase (ALT) greater than or equal to 2.5 times or Bilirubin greater than 1.5 times upper limit of normal at screening.
• Drugs known to affect creatinine clearance including cephalosporin and aminoglycoside antibiotics, flucytosine, cisplatin, cimetidine and trimethoprim within 14 days or 5 half-lives prior to the day of dosing of IMP.
• Renal group 1 (healthy subjects) exclusively: Unwilling to avoid use of prescription medicinal products or non-prescription drugs, except routine use of vitamins, occasional use of paracetamol, topical medication and contraceptives, within 14 days prior to the day of dosing.
• Renal Group 2-5 (renal impairment) exclusively: 1) Any disorder, except for conditions associated with renal impairment in the groups of subjects with reduced renal function, which in the investigator's opinion might jeopardise subject's safety, evaluation of results, or compliance with the protocol. Subjects with heart failure of functional class III-IV according to New York Heart Association (NYHA), subjects with Chronic obstructive pulmonary disease (COPD) grade 4 according to Global Initiative on Obstructive Lung Disease (GOLD), subjects with asthma step 5 according to Global Initiative for Asthma (GINA), subjects diagnosed with diabetes, subjects with uncontrolled treated/untreated hypertension (systolic blood pressure greater than or equal to 180 mmHg and /or diastolic blood pressure greater than or equal to 100 mmHg assessed in supine position) and other co-morbidities in terminal stages or which are decompensated or unstable should not be included in the study. 2) Subject requiring haemodialysis treatment unable or unwilling to undergo haemodialysis scheduled according to the standard clinical regimen throughout the trial period.

Sponsors & Collaborators

• Novo Nordisk A/S: lead

Study Sites (1)

Charité Research Organisation GmbH

Berlin, 10117, Germany

Location

Related Publications (1)

• Haahr H, Cieslarova B, Hingst JR, Jiang S, Kristensen NR, Kupcova V, Norgreen L, Wagner FH, Ignatenko S. The Effect of Various Degrees of Renal or Hepatic Impairment on the Pharmacokinetic Properties of Once-Weekly Insulin Icodec. Clin Pharmacokinet. 2024 Jun;63(6):819-830. doi: 10.1007/s40262-024-01375-2. Epub 2024 May 9.

  PMID: 38722461 RESULT

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Interventions

insulin icodec

Condition Hierarchy (Ancestors)

Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Study Officials

• Clinical Reporting Anchor and Disclosure (1452)

  Novo Nordisk A/S

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 26, 2018
• First Posted: October 30, 2018
• Study Start: November 9, 2018
• Primary Completion: September 6, 2019
• Study Completion: September 6, 2019
• Last Updated: July 12, 2024

Record last verified: 2024-07

Data Sharing

• IPD Sharing: Will share

Locations

DE (1)